Cmed Clinical Services Appoints New Chief Medical Officer
Cmed Clinical Services, an innovative, full service CRO providing services to the Biopharma industry worldwide, announced today the appointment of Dr. Bams Abila, MD, PhD, FFPM, to Chief Medical Officer.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20151009005298/en/
In this role, Dr. Abila will be responsible for leading the development and operation of Cmed’s medical function, providing leadership and strategic guidance on medical and scientific matters. He will also provide general support and training to the medical and consulting groups across Cmed to ensure the safe, legal, ethical and optimal drug development design and conduct of clinical studies. He will be based in the UK and brings to Cmed a wealth of experience in the design and delivery of clinical strategies and clinical studies with small molecules and biologicals across several therapy areas in Phases I-III.
“We are delighted to welcome Bams Abila to Cmed” said Dr. David Connelly, Cmed’s CEO. “Bams brings a vast amount of expertise, knowledge and skills in translational medicine, clinical development and drug safety, which will be very valuable not only to Cmed in driving our plans for future growth, but for our clients in maintaining and enhancing the design and conduct of their clinical trials. Bams also has a deep interest in the use of advanced data technologies to enhance the speed and efficiency of drug development which fits very well with the evolution of Cmed’s technology division.”
Dr. Abila has 10 years academic medical research experience and extensive global drug development experience spanning 25 years across several therapeutic areas within pharmaceutical settings, including Aventis, Pfizer, Astellas, AstraZeneca and GSK. He is the Founder and Principal Consultant in Pharmaceutical Medicine of Clintreq Consultancy Ltd, working with both pharmaceutical and biotech companies. He is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians (UK), Fellow of the Royal Society of Medicine (UK) and is a Member of the British Association of Pharmaceutical Physicians, the British Pharmacological Society and the American Heart Association. He is also a member of the American Society of Clinical Pharmacology and was a founding member of the society’s Biologics Community.
- ends -
Cmed is an innovative full service CRO and a software developer of smart e-clinical data capture and management technologies. Cmed was established in 2000 with the vision to conduct clinical trials better than anyone else, thus saving and helping lives. Cmed has a focus on bringing innovation to the design and conduct of clinical trials, including in the areas of clinical data capture, data management, monitoring. Cmed has two divisions: Cmed Clinical Services and Cmed Technology.
Cmed Clinical Services is a global CRO providing services to the Biopharma industry worldwide. Cmed works with clients to not only deliver the clinical trial services effectively, and with quality, passion, teamwork and superior customer service, but also, especially for full service projects, by understanding the clients commercial and business objectives. Cmed then leverages its in-depth expertise to ensure the development program and/or clinical trial is well designed and conducted as efficiently and as cost effectively as possible. Cmed has particular expertise in the design and conduct of complex, oncology and rare disease trials and the provision of Biometric functional services.
Cmed Technology designed and developed Timaeus: a unique single platform for electronic trial design, paper & electronic data capture, monitoring, coding, data management and reporting. Using distributed cloud computing and mobile technologies, Timaeus has been deployed in over 400 clinical trials and has successfully passed multiple audits. The unique Timaeus design provides a number of benefits to our clients including rapid database build (weeks not months), mid-trial updates without down-time and non-reliance on the internet. These benefits lead to many advantages including the removal of EDC build from study start-up, no restriction on investigator site selection, no negative impact on recruitment timelines due to design changes, and elevated investigator motivation.
Anna Forster, Marketing Manager
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
SHELL/BIO-BEAN20.11.2017 01:03 | pressemeddelelse
Shell, bio-bean and Coffee-Drinkers Collaborate to Help Power London’s Buses
SAMSUNG-BIOEPIS19.11.2017 23:23 | pressemeddelelse
Samsung Bioepis Receives Regulatory Approval for Europe's First Trastuzumab Biosimilar, ONTRUZANT®
FOCP19.11.2017 17:33 | pressemeddelelse
Cancer Patients, Survivors, Supporters and Caregivers Undertake UAE's First Relay for Life
ASTRAZENECA19.11.2017 00:02 | pressemeddelelse
New Data Show Benefit of Tagrisso in Patients with EGFR-mutated Non-small Cell Lung Cancer and Central Nervous System Metastases
ASTRAZENECA18.11.2017 19:22 | pressemeddelelse
New England Journal of Medicine Publishes Results of Phase III FLAURA Trial in the 1st-Line Treatment of EGFR-mutated Non-small Cell Lung Cancer
CHINA-HI-TECH-FAIR18.11.2017 10:13 | pressemeddelelse
Much-Anticipated CHTF 2017 Top 10 Products Are Unveiled
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum